Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial
G. Kheirabadi, M. Vafaie, Dorna Kheirabadi, Zahra Mirlouhi, Rasam Hajiannasab
Advanced Biomedical Research April 10, 2019 DOI: 10.4103/abr.abr_166_18 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 32 |
| Population | Adult patients with major depressive disorder who were candidates for ECT |
| Intervention | Intravenous ketamine |
| Dose | 0.5 mg/kg |
| Duration | 3-month follow-up |
| Topics | Depression Esketamine Ketamine |
| Key findings | Intravenous ketamine and ECT produced comparable antidepressant effects, with ketamine showing a nonsignificant advantage in cognitive function. |
Abstract
Background: Achieving a rapid onset and durable methods of treatment for major depressive disorders is an issue pursuing in psychiatry. This study was designed to assess the therapeutic efficacy of intravenous (IV) ketamine injection in controlling depressive symptoms in comparison with electroconvulsive therapy (ECT) in major depressed disordered patients.
Materials and Methods: Thirty-two patients over 18 years of age who were candidates for ECT were enrolled in the study. They were allocated into two groups using block design randomization. Sixteen patients received IV infusion of 0.5-mg/kg ketamine and 16 patients underwent a bitemporal ECT. To evaluate the changes in depression severity, researchers administered Hamilton Depression Rating Scale (HDRS) at baseline, before each treatment session, and four time points posttreatment (week 1 and months 1, 2, and 3). The Wechsler Memory Scale was used to evaluate the cognitive state of patients in week 1, month 1, and month 3 of the treatment.
Results: The HDRS showed improvement in depressive symptoms in both the groups with no statistically significant difference. Cognitive state was more favorable (but not significant) in the ketamine group (P > 0.5).
Conclusion: Treatment with IV ketamine in depressed people has the same antidepressant effects as ECT treatment without any memory deficiency.
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.
Citations in the library
Cited by 19
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry October 19, 2022
- Rodent ketamine depression-related research: Finding patterns in a literature of variability Behavioural Brain Research August 13, 2019
- Ketamine vs Electroconvulsive Therapy for Major Depressive Episode JAMA Psychiatry June 1, 2023
- Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis Journal of Affective Disorders March 1, 2023
and 14 more in the library
Cites 5
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS Depression and Anxiety April 6, 2016
- Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder Current Neuropharmacology March 25, 2016
- Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry January 15, 2010
- The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports December 2007